2026.11.11

SK bioscience Earns ‘Integrated Grade A’ in KCGS ESG Evaluation for 5 Consecutive Years

2026.11.05

SK bioscience Reports 21% YoY Revenue Growth in Q3 and Returns to Pre-Tax Profitability as Operational Losses ...

2026.10.29

Global Partnership Including SK bioscience Secures BARDA Funding to Advance Bundibugyo Ebola Vaccine Developme...